Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Rational molecular Assessments and Innovative Drug Selection (RAIDS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,France,Netherlands,Netherlands,Germany,Germany,Serbia,Moldova, Republic of,France,Germany,Hungary,Romania
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2017-03-31
Duration (months): 54.0
Total project cost (EUR): 7746906.48
EU funding (EUR): 5999642.4
Participants: 18
Project status: CLOSED

Cervical cancer (CC) is the second most common cause of cancer deaths in women worldwide. The main objective of the RAIDs project is to use this model system which is accessible to repeat biopsies to learn how to stratify patients into targeted therapies. The patients’ tumors will be classified into molecular subtypes based on their molecular profile by use of high-throughput technologies (sequencing, RPPA) combined with integrative bioinformatics analysis. Stratification is a learning process which will need constant readaptation. It will rely on prognostic and predictive biomolecular information gained from patients who will receive either standard therapy (the cognitive cohort) or patients who receive (first generation) targeted therapy. Bioinformatics will be an essential tool to allow integrative genome/proteome analysis and provide functional interpretation of the results at each step. Machine learning techniques will be used to select the most reliable biomarkers. These tools will be used to predict response to cc treatment or progression. Moreover, systems biology approaches will be used to unravel the gene regulatory networks and signaling pathways involved in the tumor progression and should be helpful to select predictive biomarkers and putative drug targets. Tumor material will be sampled before and following standard therapy or therapeutic HPV vaccination and/or novel targeted drug treatments. Clinical annotation by imaging methods as well as through biomarkers will have quality control procedures and relevant statistical models will be applied. RAIDS is a multidisciplinary approach integrating genomic studies, protein arrays, viral genotyping and immunohistochemical investigations on CC cells and tissues between academic clinical centers and SME’s . The project is expected to provide new tools for early diagnosis and targeted treatments exploited by SMEs and to accelerate innovation of CC therapy and improve quality of life.

Keywords: molecular targeting,patient stratification,cancer,sequencing,genomics,proteomics,bioinformatics,synthetic lethality screening,hpv vaccine,pi3k pathway,microenvironment targeting
CONSTRUCTION OF BESPOKE EVALUATION POWER MODULES~(MATPLAN) (MATPLAN)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Clean Sky
Action type: Article 171 of the Treaty
Partnership: CLEAN-SKY (Art-185)
Countries involved: United Kingdom
Call:  (SP1-JTI-CS-2011-03, 2011)
Start date: 2012-04-01
End date: 2014-03-31
Duration (months): 24.0
Total project cost (EUR): 246424.0
EU funding (EUR): 150694.0
Participants: 2
Project status: CLOSED

The objective of this proposal is to develop double side cooled packaging solutions for semiconductors eliminating the use of inherently unreliable aluminium wire bonds and replacing with seamless contacting techniques to either side of the active semiconductor thereby providing a very reliable low thermal resistance,low inductance contact . The solutions developed using innovative additive laser machining and lost wax techniques will be applicable to not only todays active components but tomorrows.Theconstructional methods developed to package the active devices will be inherently low cost compared to those associated with todays double side cooled structures. The double side cooled structures emanating out of this project will be extremely manufacturable and will offer the ultimate in longterm reliability required by the aerospace industry and will facilitate the use of higher temeprature devices operating at higher current densities and frequencies i.e SiC. In the event of system over currents the devices designed within the project are intended to fail short circuit . The ability for Europe to have an indigenous semiconductor supplier able to supply advanced components packaged in a unique thermal efficient, compact and reliable manner will give the EUs systems suppliers a significant competitive edge in aerospace and other advanced applications. A 10KW silicon carbide inverter based on specification supplied by the SGOs is envisaged.

Keywords: double side cooling,lost wax,low thermal resistance,reliable,low inductance,additive laser machining,silicon carbide,aerospace,fail short circuit
Nanoparticles in Quantum Experiments: Exploring the scientific basis of future innovative quantum technologies (NANOQUESTFIT)

Framework: FP7 — Cooperation
Programme: Information and Communication Technologies
Destination: Future and Emerging Technologies
Action type: Collaborative project
Countries involved: Austria,Germany,Israel,Italy,Switzerland
Call:  (FP7-ICT-2011-C, 2011)
Start date: 2013-01-01
End date: 2015-12-31
Duration (months): 36.0
Total project cost (EUR): 2629612.0
EU funding (EUR): 1994883.0
Participants: 5
Project status: CLOSED

Quantum phenomena are an important basis for future information processing and information acquisition technologies. They will become particularly relevant for quantum-enhanced metrology and advanced sensors, which exploit the quantum superposition principle at a mesoscopic scale. NANOQUESTFIT will prepare nanoparticles in highly non-classical quantum states and utilize them to test the linearity of quantum physics over mesoscopic distances and time scales in a mass range that has remained hitherto unexplored. This goal will be realized in an interdisciplinary effort of European experts in quantum optics, nanotechnology, chemistry, and cluster physics. NANOQUESTFIT will realize novel quantum optical elements, such as optical depletion and phase gratings, atomically thin transmission gratings, as well as doped substrates in ultra-flat silicon. This will enable quantum coherence and interference studies with objects up to and beyond 10^5 atomic mass units for the first time. For that purpose new beam methods will be explored for tailor-made nanoparticles between 10^4 and 10^7 atomic mass units. This includes the efficient volatilization and detection of chemically functionalized nanoparticles, of pure and doped nanodroplets, as well as of cold slow cluster ions. Decoherence is the enemy of all future quantum-based technologies. The consortium will therefore investigate environmental decoherence with objects in a complexity class that is expected to become relevant in future quantum devices. Advanced experiments in NANOQUESTFIT will allow defining new constraints on unconventional extensions of quantum theory, which will be explored and elaborated on with regard to their conceptional consistency. Since the linearity of the Schrödinger equation is the very basis for the majority of current quantum information concepts this has direct implications for QIPC. NANOQUESTFIT works at the cutting edge of modern science to lay the scientific ground for a better understanding of practical and fundamental limits of future quantum technologies. It will also generate spin-offs for new quantum-enhanced sensing devices: in particular the beam splitter technologies developed in NANOQUESTFIT will be applicable to a wide range of matter waves composed of atoms, molecules and genuine nanoparticles.

Keywords: foundations of quantum science and technology,quantum-classical transition,decoherence,nanoparticle technologies,quantum enhanced measurements
Clinical Development of Nitisinone for Alkaptonuria (DEVELOPAKURE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Slovakia,France,Italy,United Kingdom,Sweden,Slovakia,Netherlands,Denmark,France
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2019-01-31
Duration (months): 75.0
Total project cost (EUR): 11208296.05
EU funding (EUR): 5999999.0
Participants: 15
Project status: CLOSED

DevelopAKUre is a proposal to fund the clinical development of an orphan designated drug, nitisinone, for the treatment of a rare Mendelian disease, Alkaptonuria (AKU). AKU is a genetic deficiency of homogentisic acid dioxygenase, causing high levels of homogentisic acid (HGA). Oxidation of HGA to pigment polymer, termed ochronosis, alters connective tissues. This leads to multisystemic damage dominated by premature severe arthritis. Currently, multiple arthroplasty is inevitable since AKU is incurable and there is no effective palliative therapy. No data exists regarding the presence or absence of ochronosis before age 30 years. Hence, it is unknown whether treatment is necessary before then. A potential HGA-lowering therapy with nitisinone is available, but lacks outcome data. Thanks to our existing successful fundamental and clinical research (cell models, animal models, natural history studies), we are now ready for the final stage of clinical development of nitisinone for AKU in order to overcome these challenges. This will involve a dose finding study, a phase 3 clinical trial to prove efficacy, and a cross-sectional study in children and young adults to determine when to start treatment. The results of DevelopAKUre will allow us to make the case to the European Medicines Agency for marketing authorisation of nitisinone for AKU, thereby contributing to the goal of the International Rare Diseases Research Consortium of 200 new therapies by 2020. Our consortium has worked together for five years already. It includes Liverpool University’s AKU Research Team as the lead applicant, the AKU Society UK patient group for dissemination and patient recruitment, three SMEs (Denmark, Netherlands) for biomarker analysis and clinical trial coordination, an industry partner (Sweden) supplying the drug and regulatory support, three universities (UK, Italy, Slovakia) for the analysis of data, and three clinical trial centres (UK, France, Slovakia) to reach required numbers.

Keywords: alkaptonuria,aku,ochronosis,nitisinone,orfadin,ntbc,homogentisic acid,hga,homogentisic acid dioxygenase,hgd,developakure,clinical trial,orphan drug,orphan disease,rare disease.
Consumer-safe and thermally-stable bioplastic formulation with controlled biodegradation properties for agricultural and horticultural accessories (DEGRICOL)

Framework: FP7 — Capacities
Programme: Research for the benefit of SMEs
Destination: Research for SME associations
Action type: Research for the benefit of specific groups
Countries involved: France,United Kingdom,France,Spain,Netherlands,Türkiye,Germany,Spain,Spain
Call:  (FP7-SME-2012, 2012)
Start date: 2012-11-01
End date: 2015-10-31
Duration (months): 36.0
Total project cost (EUR): 2333073.38
EU funding (EUR): 1697279.13
Participants: 9
Project status: CLOSED

The consumption of plastic materials in agriculture and horticulture in EU has dramatically increased in the last decades posing serious problems of environmental and economic concerns. Agriculture and Horticulture sector generates about 1.2 Mt of plastic waste per year in the Europe, where almost 30% (336 Kt) are coming from accessories such as nets and clips for plant support and plastics pots and trays for greenhouses and bed-seeds. The recycling of these products is very expensive and time-consuming due to the high labour cost for the collection and the impossibility to be automatized. In addition, these products must be low-cost and stable during storage and use. So far, existing bio-degradable plastics have serious product costs and performance issues that are unacceptable to agricultural-horticultural professionals. In addition, there are no clear methods to test the migration levels of biodegradable agricultural plastics in contact with agri-food during their growth. By joining the efforts of three National Associations from Agricultural, Bioplastic and Food Quality sectors, DEGRICOL Consortium will develop cost-competitive, 100% natural-based bioplastic formulation based on a thermally stable and crystalline PLA matrix for the manufacturing of Agriculture and Horticulture accessories. Such formulation will contain natural fillers (such as lignin or chitosan) isolated from animal- and agro-residues to further reduce costs and, and bio-surfactants (humic acid-like) isolated from compost of urban food or agro-residues to improve and control the biodegradation process according to their use. In addition, These accessories, pots and clips (manufactured through injection moulding process) and tutors and nets (trough fibre-extrusion process) will have the requirements necessary to fulfil the normative EN13432 regarding biodegradation and compostability, and Directive 2007/19/CE regarding total Migration Limit of plastics in contact with food-products.

Keywords: bioplastic,pla,agriculture and horticulture accesories
Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) (NET4CGD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,United Kingdom,Germany,Switzerland,France,Germany,Germany,Germany,France
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-12-01
End date: 2018-05-31
Duration (months): 66.0
Total project cost (EUR): 8302977.6
EU funding (EUR): 5999607.0
Participants: 11
Project status: CLOSED

This project is focused on the clinical development of a new orphan drug that can rapidly become a new treatment option for patients with the X-linked form of chronic granulomatous disease (X-CGD). This rare primary immune deficiency of phagocytes is caused by mutations in the gp91phox gene. Affected patients are highly-susceptible to infections and develop inflammatory granulomas. Several members of the Net4CGD consortium have already attempted hematopoietic gene correction of X-CGD using gp91 gammaretroviral gene transfer vectors. While functional correction and clinical benefit was initially achieved, problems arose, linked to insertional mutagenesis, vector silencing and lack of long-term engraftment. Net4CGD proposes future trials to achieve (i) effective transduction of hematopoietic cells, (ii) physiological expression of the transgene and (iii) long-term engraftment of gene modified cells. A new lentiviral vector (LV) was developed to express gp91phox in myeloid cells. Encouraging results obtained in preclinical studies and through the compassionate treatment of a patient, prompt us to test the LV in a multi-center study in several European centers expert in CGD, under the sponsorship of a rare disease specialist. The tasks include i) Manufacturing clinical grade vector to support clinical studies, ii) Conducting a multi-center phase I/II trial in eligible X-CGD patients, with LV gene-modified autologous hematopoietic stem cells to evaluate the safety and efficacy of the procedure iii) Ensuring high-quality and harmonization of products and procedures to facilitate future product registration iv) Obtaining state-of-the art information on biological efficacy and safety in patients by assessing immune restoration and large-scale integrome data. If positive, this study will be used to register the orphan drug. The treatment is expected to improve patients’ quality of life and will reduce the economical burden of CGD. Results should benefit other RD.

Keywords: rare disease,clinical trial,orphan drug,lentiviral vector,gene therapy,chronic granulomatous diseases.
Glioma Actively Personalized Vaccine Consortium (GAPVAC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Denmark,Germany,Switzerland,Germany,Israel,Netherlands,Spain,United Kingdom
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2017-01-31
Duration (months): 51.0
Total project cost (EUR): 7918396.0
EU funding (EUR): 5970436.0
Participants: 13
Project status: CLOSED

Glioblastoma (GBM) is a rare (2-3 incidences in 100,000) and fatal disease. Each year, approximately 13,000 new cases of GBM are diagnosed in Europe. The 5-year survival rate of this highly aggressive tumor entity under conventional therapy is less than 6%. Currently available therapeutic options neglect the individuality of each patients’ disease and only temporarily influence tumor progression with poor effect on overall survival. Introduction of novel highly innovative personalized approaches would have tremendous impacts for the life course of affected patients without additive toxicities. Active cancer immunotherapy aims to trigger the patients´ immune system, specifically cytotoxic T lymphocytes (CTLs) and T helper cells, to defend the body against the cancerous disease. The Glioma Actively Personalized Vaccine Consortium (GAPVAC) aims to conduct a highly innovative pioneering project with active personalized immunotherapy to improve patient treatment. In a Phase I/II study at the center of this proposal, glioblastoma patients will receive a fully personalized peptide-based vaccine as a result of full-genome sequencing and complete peptidomics analysis of the patient’s tumor. Thus, the latest developments in next-generation sequencing, proteomics, immunology, biomarker research and small-scale GMP peptide manufacturing will be uniquely combined to deliver the next generation of personalized medicine to cancer patients. GAPVAC’s goal is to test safety, feasibility and efficacy (biological and early clinical) of this totally novel, completely personalized approach of immunotherapy. GAPVAC is therefore specifically answering the call HEALTH.2012.1.2-1 Development of technologies with a view to patient group stratification for personalized medicine applications by a 4 years project.

Keywords: glioblastoma immunotherapy peptide vaccine personalized medicine biomarker immunomonitoring next generation sequencing peptidomics individualized therapy rare disease glioma
European Communication on Research Awareness Needs (ECRAN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Italy,France,United Kingdom,Denmark,Germany,Germany,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-09-01
End date: 2014-08-31
Duration (months): 24.0
Total project cost (EUR): 970625.6
EU funding (EUR): 892666.0
Participants: 9
Project status: CLOSED

The ECRAN (European Communication on Research Awareness Needs) project is designed to develop a portfolio of open educational resources, including a film, for the general population about the challenges raised by independent clinical research. The European Commission (FP7 Health Priority) decided to allocate substantial funding to independent (investigator-driven) clinical trials. Together with member states, the FP7 infrastructure unit supports the preparation and operation of a pan-European infrastructure for clinical trials (ECRIN). Through these instruments, Europe has the capacity to design and conduct independent, multinational clinical trials. The objective of the ECRAN project is to develop tools to communicate key messages to citizens, patients, healthcare professionals, researchers, policymakers and society about independent, multinational clinical research. These messages will focus on: i) the importance of public understanding of the need for and basic principles of clinical trials, fostering active involvement of patients in trials and of their representatives in trial design; ii) the need for independent clinical trials driven by healthcare issues, to optimise treatment strategies through comparison of benefits and harms of multiple therapeutic options, supporting evidence-based clinical practice and reduction in healthcare inequalities; iii) the need for transparency and optimal use of data, to promote the cost-effectiveness of treatments and to reduce the economic burden of diseases; iv) the need for multinational cooperation, taking advantage of Europe’s population size and diversity, and of its medical expertise. These objectives will be addressed using communication tools, including: a website, with an online database of open educational resources in different European languages; a film on clinical trials, dubbed in many languages, which is envisaged as a keystone of this initiative; an international event on multinational clinical trials.

Keywords: clinical trials,investigator-driven,multinational,fp7 funding,communication,patients,film
European Network of Knowledge Transfer in Health (ENTENTE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: France,Belgium,Belgium,Belgium,Belgium,United Kingdom,Netherlands
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-09-01
End date: 2015-08-31
Duration (months): 36.0
Total project cost (EUR): 2135541.04
EU funding (EUR): 1999985.0
Participants: 7
Project status: CLOSED

The objective the ENTENTE project is to reinforce knowledge transfer (KT) offices in universities, public research organisations, hospitals and to promote industry academia transnational collaboration in the health sector. This will be achieved through seven sub-objectives: 1-The development of a web platform for shared learning and networking including best practices, video interviews, networking and e-learning modules for scientists, hospitals, program managers and policy makers, enabling continuous updating on innovative measures and interactive networking among all type of actors. 2-The continuous identification and promotion of good knowledge management and KT practices in the EU MS and AC, providing evidence on best practices including standardisation and key components for running a successful KT organisation. 3-Give visibility to best achievements at the EU level, including impact of legislation and tax incentives on technology transfer and innovative SMEs, as well as good KT from EU-funded projects. 4-The development an online repository of best practices in KT, included in the web platform and built on existing repositories. Its active promotion will be secured through the events that will be organised during the project. 5-The promotion of interaction between universities, industry, investors and individual researchers with the organisation of workshops, partnering events and staff exchanges, between different types of actors. 6-The organisation of national activities, based on the activities of ASTP. 7-The organisation of two ENTENTE events during the project lifetime in Brussels and elsewhere in Europe engaging all stakeholders at large, including the DG R&I promoting collaboration and exchanges with the industrial tissue. The main result of the ENTENTE project will be the creation of a steady pan-European KT activity between universities, SMEs, PROs and Industry as well as investors leading to an improvement of the global European knowledge.

Keywords: knowledge transfer,technology transfer,network,staff exchange,best practice,health,industry,academia,investors,partnering